Dr. Raffit Hassan, MD

Senior Investigator

National Cancer Institute (NCI)

Bethesda, MD

  • Head, Thoracic and Solid Tumor Immunotherapy Section

Dr. Raffit Hassan is among the leading authorities in mesothelioma mesothelin-targeted therapies whose work and published research informs MesoWatch's medical coverage. This page collects publicly available information about their role, institutional affiliations, and contributions to the field.

Areas of Expertise

  • Mesothelin-Targeted Therapies
  • CAR-T Cell Research
  • Immunotoxins
  • BAP1 Clinical Trials

Notable Contributions

  • Pioneered mesothelin as cancer therapy target
  • Developed SS1P, LMB-100, Amatuximab
  • Leading CAR-T clinical trials
  • Nature Medicine publication (2023)

Public Profile and Verification

The following links lead to publicly available institutional and academic profiles for Dr. Raffit Hassan:

MesoWatch Coverage Areas Informed by This Expertise

Disclosure

MesoWatch is an independent journalism organization. The expert authorities profiled here are not employees, paid consultants, or contracted reviewers of MesoWatch. Their inclusion reflects the body of public research and clinical leadership that shapes the standard of care in mesothelioma. Where MesoWatch articles cite or build on the published work of these authorities, the underlying primary source (peer-reviewed publication, institutional press release, or clinical trial record) is linked in the article's Sources section.

For questions about how an expert is referenced, contact [email protected].